tildrakizumab

Home
Ligands
tildrakizumab

GtoPdb Ligand ID: 8093

Synonyms: Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn

tildrakizumab is an approved drug (EMA & FDA (2018))

Comment: Tildrakizumab is a monoclonal antibody directed against the p19 subunit of IL-23 (IL-23A). It exhibits efficacy in treating psoriasis [1,4]. This biologic agent may be beneficial for patients who do not tolerate current antitumour necrosis factor (TNF) therapies.

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Tildrakizumab inhibits IL-23 receptor signalling by sequestering free ligand. This action down modulates the release of pro-inflammatory cytokines and chemokines, and reduces disease pathology.

Immunopharmacology Comments

Tildrakizumab inhibits IL-23 receptor signalling by sequestering free ligand. This action down modulates the release of pro-inflammatory cytokines and chemokines, and reduces disease pathology.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Psoriasis	Disease Ontology: DOID:8893	Approved drug for moderate to severe plaque psoriasis.	3